Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alisporivir + ribavirin
- Development stage
- Phase 2
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Alisporivir + ribavirin** is an investigational oral combination therapy for hepatitis C virus (HCV) infection. **Alisporivir** is a host-targeting antiviral that inhibits the peptidyl-prolyl isomerase activity of cyclophilin A, a cellular protein essential for HCV replication, conferring pangenotypic anti-HCV activity and a high barrier to resistance. **Ribavirin** is a guanosine analogue antiviral that works through multiple mechanisms, including inhibition of inosine monophosphate dehydrogenase (IMPDH), inducing viral error catastrophe (RNA mutagenesis), inhibition of viral RNA polymerase, and immunomodulation. Clinical studies have shown that the combination (with or without interferon) improves rapid virological response and sustained virological response, especially in HCV genotype 2 or 3, with a favorable safety profile in interferon-free regimens. Alisporivir and ribavirin have not been approved as a fixed combination product; their use in combination is investigational, mainly assessed in clinical trials for HCV.
- Other names
- ALV + RBV
02
Targets
PPIA (Peptidyl-prolyl cis-trans isomerase A)NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)IMPDH (Inosine-5'-monophosphate dehydrogenase 1)
Beyond the preview
Go deeper on alisporivir + ribavirin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alisporivir + ribavirin.